Introduction
To implement the resolutions of the Executive Yuan's Bio Taiwan Committee (BTC), the National Science and Technology Council (NSTC) is leveraging AI to accelerate the development of new drugs and preclinical applications in Taiwan, promote cross-sectoral and interdisciplinary collaboration in the biotechnology and pharmaceutical industry, and establish a comprehensive non-clinical drug development process service model. This initiative aims to integrate the preclinical trial capabilities of Taiwan's academia, research institutions, and industry, and actively promote the Artificial Intelligence-Driven Drug Development Program (115-118). Among the key projects of this four-year program is the establishment of the "Taiwan Contract Research One-Stop Service, T.CROSS."
After more than six months of preparation, the "Taiwan Contract Research One-Stop Service, T.CROSS" is officially established in January 2026. Its purpose is to strengthen the integration of Taiwan's preclinical research and AI-Driven Drug Development Projects, and to build a cross-domain collaborative industry service ecosystem.
Mission and Objectives
- To establish a leading preclinical R&D alliance in Taiwan.
- To integrate the core strengths of five major R&D institutions in Taiwan: National Center for Biomodels (NCB) of the National Institutes of Applied Research, Biomedical Translation Research Center of Academia Sinica, Industrial Technology Research Institute (ITRI), Development Center for Biotechnology (DCB), and National Health Research Institutes.
- To provide a complete one-stop CRO service, accelerating the translation and industrialization of innovative achievements in biotechnology and medicine.
We integrate national-level research resources and establish a comprehensive preclinical trial service system.
We provide research services that meet international standards to help manufacturers accelerate product development.
We promote the translation of academic and research findings and drive the development of Taiwan's biotechnology and pharmaceutical industry.
Our Technical Expertise
Animal Testing Services
Provide species research services for new drug development, including rodent and medium-to-large animal testing services.
GLP Quality Management
Possess extensive experience in new drug development and GLP quality management.
Preclinical R&D Experience
Have preclinical research and development experience in chemical drugs, biologics, nucleic acid drugs, and cell/gene therapy for cancer, infections, neurodegeneration, immune and metabolic diseases.
GMP/CDMO Production
Provide services including novel dosage form research, antibody/protein engineering, nucleic acid drug design, and GMP/CDMO manufacturing.
Drug Analysis Platform
Possess drug analysis platform and immunotoxicology evaluation capabilities.